Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
